RxDoctor Payments Data

Jayakumar Vidhun, MD

Nephrology · Whittier, CANPI 1275685638

Payments from drug & device makers

$418,624in general payments, 2019–2025

Across 810 payments — averaging $516.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$302K
  • AstraZeneca$90K
  • Mallinckrodt Hospital Products Inc.$20K
  • Calliditas Therapeutics US Inc.$4K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
  • Travere Therapeutics, Inc.$280
  • plus $905 from 14 others

What the payments were for

  • Consulting fees$30,8577%
  • Speaking & faculty fees$329,56379%
  • Travel & lodging$43,11710%
  • Food & beverage$15,0094%
  • Education$370%
  • Gifts$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$418,624 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$286,496
Medicare patients
519
Services billed
2,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol248$170,065
FilspariSparsentan12$134,293
EliquisApixaban67$50,636
LokelmaSodium Zirconium Cyclosilicate56$41,790
JanuviaSitagliptin Phosphate23$30,865
JardianceEmpagliflozin31$24,036
OzempicSemaglutide17$20,802
KerendiaFinerenone22$13,777
DapagliflozinDapagliflozin Propanediol23$12,200
Calcium Acetate49$5,209
Praluent PenAlirocumab11$5,060
Cinacalcet Hcl12$4,561
Sevelamer Carbonate23$3,319
Labetalol Hcl78$2,528
Losartan Potassium161$1,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$90,410$211,855304 claims
Travere Therapeutics, Inc.Filspari$280$134,29312 claims
Boehringer IngelheimJardiance$23$24,03631 claims
Novo NordiskOzempic$36$20,80217 claims
BayerKerendia$39$13,77722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →